Skip to main content
CSL Behring supports the International Society on Thrombosis and Haemostasis annual congress.)

ISTH 2024

International Society on Thrombosis and Haemostasis (ISTH) Congress 2024

22–26 June 2024 | Bangkok, Thailand

One of the Broadest Portfolios in Haematology

HEMGENIX® (etranacogene dezaparvovec), IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rFIX-FP)), HAEMATE P® (Von Willebrand factor/factor VIII), VONCENTO® (Human Coagulation Factor VIII/Von Willebrand Factor Complex) and KCENTRA® (Prothrombin Complex Concentrate (Human)) are not registered and not approved for use in Thailand. Registration conditions differ internationally, please refer to the local Prescribing Information in your country.

Consult the CSL Behring Global Products List to see what is available.

Report an undesirable effect

If you encounter any side effect(s) to a CSL Behring product, please contact us.

June 2024